|- candidate number||14155|
|- NTR Number||NTR3770|
|- ISRCTN||ISRCTN wordt niet meer aangevraagd.|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||4-jan-2013|
|- Secondary IDs||2012/259 METC|
|- Public Title||Pain from intraocular injections with ultrathin needles compared to regular needles.|
|- Scientific Title||Pain experienced from intravitreal injection with a 33 gauge needle vs a 30 gauge needle: is thinner better?|
|- hypothesis||Intravitreal injections are used more and more frequently in ophthalmology. This trend is mostly caused by the arrival of anti-VEGF agents used for age-related macular degeneration, diabetic macular edema and macular edema secondary to retinal vein occlusion. It is known from clinical practice that discomfort and pain at the injection site are common side effects from intravitreal injections. In current practice 30 gauge needles are often used for intravitreal injections with bevacizumab and they have been shown to cause less pain and vitreal reflux than thicker needles. We expect pain level can be lowered even further by reducing needle width to 33 gauge. |
|- Healt Condition(s) or Problem(s) studied||Pain, Injection, Intraocular, Intravitreal|
|- Inclusion criteria||Patients with an indication for at least two consecutive monthly intravitreal injections with bevacizumab. |
|- Exclusion criteria||Patients unable to state pain levels or give written informed consent. |
|- mec approval received||no|
|- multicenter trial||no|
|- Type||2 or more arms, randomized|
|- planned startdate ||10-jan-2013|
|- planned closingdate||21-feb-2013|
|- Target number of participants||75|
|- Interventions||Two consecutive intraocular bevacizumab injections with a 33G and 30G needle.|
|- Primary outcome||Pain score on 100mm numeric rating scale.|
|- Secondary outcome||Patientsí stress levels and expectation questionnaire scores.|
|- Timepoints||Injection nr 1 at timepoint 0 and injection nr 2 after 1 month. |
|- Trial web site||N/A|
|- status||open: patient inclusion|
|- CONTACT FOR PUBLIC QUERIES||Drs. F. Asten, van|
|- CONTACT for SCIENTIFIC QUERIES||Drs. F. Asten, van|
|- Sponsor/Initiator ||Radboud University Medical Center Nijmegen|
(Source(s) of Monetary or Material Support)
|Radboud University Medical Centre Nijmegen|
|- Brief summary||Rationale: |
Pain and discomfort at the injection site are common side effects of intravitreal injections with bevacizumab. In current practice 30 gauge needles are regularly used for these intravitreal injections and they have been shown to cause less pain than thicker needles.
The main objective of this study is to evaluate whether pain caused by intravitreal bevacizumab injections with the regular 30 gauge needle can be reduced by using a 33 gauge needle.
Double-blind, randomized, cross-over trial.
Patients eligible for treatment with two consecutive injections with intravitreal bevacizumab.
All patients receive two consecutive intravitreal injections with bevacizumab 1.25 mg in 0.05 ml as decided by their treating physician. Patients are randomized to receive the first intravitreal injection either with the regular 30 gauge or the 33 gauge needle. The interval for the second injection will be 2-6 weeks and will be performed using the alternate injection needle.
The primary outcome is the degree of pain during the intravitreal injection, as measured on a 100 mm numeric rating scale (NRS) of pain intensity. The secondary endpoint is anxiety experienced during the injection procedure determined using the hospital anxiety depression scale (HADS) and the state-trait anxiety inventory (STA-I).
Burden and risks associated with participation:
Patients are asked to fill in a HADS and STA-I questionnaire prior to the two consecutive injections and to score the degree of pain experienced during the intravitreal injections on a 100 mm NRS immediately after the procedure. There are no known risks associated with a higher needle gauge. Patients will be informed of the risks related to the injection procedure itself, namely endophthalmitis, retinal detachment and increased risk of cataract, which are the same as in normal clinical practice and are unlikely to be associated with needle gauge.
|- Main changes (audit trail)|
|- RECORD||4-jan-2013 - 16-jan-2013|